Overcoming PARPi resistance in ovarian cancer: from biology to clinical application

High-grade serous ovarian carcinoma is a relatively uncommon neoplasm but with a very high lethality. In recent years, the use of PARP inhibitors, in maintaining the first line of treatment, has significantly improved the prognosis of these patients. 

Unfortunately, over time, most of them develop disease recurrences that are resistant to treatment, leaving few valid therapeutic options. 

The aim of this project is to understand the causes of the development of resistance to treatment and consequently identify strategies to overcome these resistances and develop predictive biomarkers of response. 

Using a multidisciplinary approach and highly innovative technologies, we expect to provide useful elements for a better molecular characterization of patients in order to identify new and more effective therapies and offer increasingly personalized treatment modelled on the characteristics of each tumor.